GLP-1 Peptide Atlas, by Delfa

CompletedPhase NA

GLP-1 Medicines and Mental Health Changes

Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity

Lead sponsor

University of California, San Diego

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Beck Depression Inventory-2

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07368855

Org study IDE250185

Timeline

Milestones

Study start2024-05-01actual

Primary completion2025-07-01actual

Study completion2025-07-01actual

Study first posted2026-01-27actual

Last update posted2026-01-27actual

Assets

Investigational agents

Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Veterans receiving care at the VA San Diego Healthcare System

Exclusion criteria

•VASDHS Veterans not receiving GLP-1 medicines for obesity through the weight control clinic

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Patient-reported / QoL

1 endpoint

Primary/protocol endpoint

Beck Depression Inventory-2

Time frame:Six months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.